Quantcast
Last updated on April 23, 2014 at 12:36 EDT

Latest C-peptide Stories

2010-05-06 08:10:00

JERUSALEM, Israel, May 6, 2010 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals Inc. (OTCBB: ORMP), a developer of alternative drug delivery systems, reported today results for the recently completed Phase 2b non-FDA clinical trial of its flagship oral insulin capsule, ORMD-0801. The randomized, double-blind, placebo-controlled, multi-centered study conducted in South Africa evaluated responses of 29 Type 2 diabetes patients to ORMD-0801. Insulin-loaded or placebo capsules were...

2010-05-04 06:30:00

CRANBURY, N.J., May 4 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 7,709,484, titled "Substituted Melanocortin Receptor-Specific Piperazine Compounds," today. The claims in the issued patent relate to small molecule compounds which bind to melanocortin receptors. Palatin has received Notices of Allowance from the U.S. Patent and Trademark Office on four additional patent applications relating to...

2010-02-25 09:01:00

ST. LOUIS, Feb. 25 /PRNewswire/ -- Supelco, a division of Sigma-Aldrich® (Nasdaq: SIAL), announced today the launch of Ascentis Express Peptide ES-C18, a high-speed, high-performance liquid chromatography (HPLC) column based on a new 160 angstrom Fused-Core(TM) particle design. This column design exhibits very high column efficiency, providing a stable, reversed phase packing with a pore structure and pore size that is optimized for reversed-phase HPLC separations of...

2010-01-26 14:00:00

SALEM, N.H., Jan. 26 /PRNewswire/ -- ALPCO Diagnostics has developed two new low-sample volume ELISAs for the quantitative analysis of total proinsulin (I and II) in rats and mice. These methods were developed using synthetic rat and mouse proinsulin I and II expressed in bacteria and purified from inclusion bodies, and were first introduced in an abstract presented at the Upper Midwest Islet Club Meeting in June 2009. Both the Rat Proinsulin ELISA and Mouse Proinsulin ELISA allow for the...

2010-01-07 06:55:00

CAMBRIDGE, Mass., Jan. 7 /PRNewswire/ -- Tolerx, Inc., today announced the completion of patient enrollment in its Phase 3 clinical study DEFEND-1, which is evaluating the safety and efficacy of otelixizumab, a targeted T cell immunomodulator, in patients with new-onset autoimmune type 1 diabetes. The DEFEND-1 (Durable Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes) study enrolled 240 patients, aged 12-45 years with newly diagnosed autoimmune type 1 diabetes. The...

2009-12-01 06:30:00

CRANBURY, N.J., Dec. 1 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) today announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 7,622,440, titled "Cyclic Natriuretic Peptide Constructs." The claims in the issued patent cover a family of cyclic compounds that bind to natriuretic peptide receptor A (NPRA), including PL-3994, Palatin's lead heart failure drug candidate. "Our natriuretic compounds, including PL-3994, address significant unmet...

2009-10-07 17:29:00

BOULDER, Colo., Oct. 7 /PRNewswire/ -- Waleed Danho, Ph.D., Distinguished Research Leader at Roche was honored last week as the 2009 recipient of the Meienhofer Award for excellence in peptide chemistry at the international peptide symposium, RCCPS (http://www.rochecolorado.com/PeptideSymp09/). Hosted by Roche Colorado, the company's peptide manufacturing facility in Boulder, RCCPS is the only global conference exclusively dedicated to peptides. For Danho, who has a world-wide reputation...

2009-09-29 06:00:00

SAN FRANCISCO, Sept. 29 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX), a company focused on the development of novel therapeutics for heart failure patients, today announced the appointment of Arie S. Belldegrun, M.D., FACS to its board of directors. Dr. Belldegrun is an accomplished scientist and entrepreneur, with over 20 years of biotechnology experience in academia and industry. "We are honored to have Dr. Belldegrun join our Board of Directors," said Joshua...

2009-09-25 06:00:00

SAN FRANCISCO, Sept. 25 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX), a company focused on the development of novel therapeutics for heart failure patients, today announced the appointment of Frank Litvack, M.D., to its Board of Directors. Dr. Litvack is a seasoned veteran of the cardiovascular healthcare space, with over 25 years of academic and industry experience. "We are excited to welcome Dr. Litvack to our Board of Directors," said Joshua Kazam, CEO of Nile. "As...

2009-09-14 07:51:00

SAN FRANCISCO, Sept. 14 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX), a company focused on the development of novel therapeutics for heart failure patients, today announced that there will be a poster presented at the 13th Annual Scientific Meeting of the Heart Failure Society of America in Boston. The abstract presents data from a Phase 1b study of CD-NP in chronic heart failure patients. In this study, a 24-hour infusion of CD-NP resulted in improved renal function...